Cargando…

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Detalles Bibliográficos
Autor principal:	Bersanelli, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117596/ https://www.ncbi.nlm.nih.gov/pubmed/32212881 http://dx.doi.org/10.2217/imt-2020-0067

Ejemplares similares

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Challenges and Controversies to Testing for COVID-19
por: Binnicker, Matthew J.
Publicado: (2020)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19
por: Gatto, Lidia, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality
por: Shimoda, Masashi, et al.
Publicado: (2016)

Multiple comparisons controversies are about context and costs, not frequentism versus Bayesianism
por: Greenland, Sander, et al.
Publicado: (2019)

The controversial bond between COVID-19 and bacterial superinfections
por: Bonazzetti, Cecilia, et al.
Publicado: (2023)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies
por: Castelli, Valeria, et al.
Publicado: (2021)

Controversies in varicocele repair – much ado about nothing?
por: Shen, Jim Ken-Chie, et al.
Publicado: (2016)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer
por: Rhea, Logan P, et al.
Publicado: (2021)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

Management of immune checkpoint therapy for patients with cancer in the face of COVID-19
por: Shen, Chen, et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Communicating COVID-19 vaccines: lessons from the dengue vaccine controversy in the Philippines
por: Lasco, Gideon, et al.
Publicado: (2021)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
por: González-Navajas, Jose M., et al.
Publicado: (2021)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

“TO BE OR NOT TO BE” GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023)

Controversies concerning the diagnosis and treatment of bipolar disorder in children
por: Parens, Erik, et al.
Publicado: (2010)

Recently published papers: A number of treatment controversies
por: Williams, Gareth
Publicado: (2003)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
por: Yu, Peter Paul, et al.
Publicado: (2019)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sfhp2qe04tmcrl9kj23ov4ks2t